Processing your payment...
Please do not close your browser.

Acinetobacter Infections Treatment Market Growth, Trends and Forecast (2022-2029) By Type (Sulbactam, Carbapenems, Aminoglycosides) By Application (ETX2514, VXD-001, Small Molecule Antibiotic, AR-401 mAB) and By Regions

12 Jul, 2022 | 164 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Acinetobacter Infections Treatment Market will register a CAGR of  % in terms of revenue and the global market size will reach USD xx Billion by 2029.

Acinetobacter Infections Treatment Market Overview

A rod-shaped, gram-negative coccobacillus bacterium is known as Acinetobacter baumannii. People with compromised immune systems are increasingly being affected by hospital-acquired bacterial infections caused by this bacterium. Infections caused by Acinetobacter typically target organ systems with high fluid content, such as the peritoneal fluid, respiratory tract, urinary tract, and cerebral fluid, which can result in infections connected to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. Due to the rising frequency of hospital-acquired infections, the acinetobacter infections treatment market is now a viable business enterprise. This makes this sector a very lucrative and alluring market.

The advent of innovative treatments that are safe and highly effective, as well as the rising incidence rate of hospital-acquired bacterial infections, are the main drivers of the market for treating acinetobacter infections. Moreover, this market is anticipated to be somewhat driven by the development of customized medications that are created individually for each individual patient based on their genetic makeup. The market size of the entire market for the treatment of Acinetobacter infections is predicted to increase with the introduction of novel, cost-effective infection control technologies and solutions. The market for the treatment of Acinetobacter infections is also anticipated to develop as the incidence rate of traumatic injuries rises.

What is our Acinetobacter Infections Treatment Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of xx % during the review period (2022 to 2029).

 

By Type

  • Sulbactam
  • Carbapenems
  • Aminoglycosides
  • Polymyxins
  • Tetracyclines
  • Others

 

By Application

 

 

 

 

  • ETX2514
  • Nacubactam RG6080
  • Arenicin
  • VXD-001
  • Small Molecule Antibiotic
  • AR-401 mAB
  • LCB01-0371 (PO)
  • GN-4474
  • Antibacterial Antibody

 

 

 

By Companies

  • Entasis Therapeutics
  • Roche
  • Adenium Biotech
  • Vaxdyn
  • Hsiri Therapeutics
  • Aridis Pharmaceuticals
  • LegoChem Biosciences
  • Atterx Biotherapeutics
  • Achaogen
  • Peptilogics
  • Sealife PHARMA
  • Shionogi
  • Techulon
  • Tetraphase Pharmaceuticals

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

164

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What is the current Market size and compound annual growth rate (CAGR) of the Acinetobacter Infections Treatment Market during the forecast period (2022-2029)?

The Acinetobacter Infections Treatment Market is growing at a CAGR of xx % over the next 7 years.

Who are the key players in Acinetobacter Infections Treatment Market?

Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife PHARMA, Shionogi, Techulon, Tetraphase Pharmaceuticals, Others.

What region does this Acinetobacter Infections Treatment Market report covers?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What are the significant Type of Acinetobacter Infections Treatment Market?

Sulbactam, Carbapenems, Aminoglycosides, Polymyxins, Tetracyclines, Others.

What are the significant Application of Acinetobacter Infections Treatment Market?

ETX2514, Nacubactam RG6080, Arenicin, VXD-001, Small Molecule Antibiotic, AR-401 mAB, LCB01-0371 (PO).

Who are the Major Players in Acinetobacter Infections Treatment Market?

Market Growth Reports lists out all the Acinetobacter Infections Treatment Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife PHARMA, Shionogi, Techulon, Tetraphase Pharmaceuticals, Others

Industry News:

WALTHAM, Mass., May 17, 2022 - Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California.

What are the major Types and Applications for Acinetobacter Infections Treatment Market?

By Type, it is segmented into

  • Sulbactam
  • Carbapenems
  • Aminoglycosides
  • Polymyxins
  • Tetracyclines
  • Others

By Application, it is segmented into

  • ETX2514
  • Nacubactam RG6080
  • Arenicin
  • VXD-001
  • Small Molecule Antibiotic
  • AR-401 mAB
  • LCB01-0371 (PO)
  • GN-4474
  • Antibacterial Antibody

Acinetobacter Infections Treatment Market Regional Analysis

Geographically, the market for treating Acinetobacter infections is dominated by North America. This area is able to maintain its leadership position internationally because of the strict hospital regulatory standards and improved government assistance for managing and preventing hospital-acquired Acinetobacter infections. Due to the rise in hospital-acquired bacterial illnesses, Europe grows at a rate that is second only to North America in terms of population. The majority of hospitalized patients in England, according to the Health Protection Agency (HPA), get a bacterial infection at some point during their hospitalization. However, it is anticipated that other regions, like South East Asia, the Middle East, and Latin America, may soon provide potential opportunities. because of the population's expanding disposable income, the rise in bacterial illnesses, and the expansion of the healthcare system.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL ACINETOBACTER INFECTIONS TREATMENT BY TYPES
    3. GLOBAL ACINETOBACTER INFECTIONS TREATMENT BY APPLICATION
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST ON MATERIALS
    3. OPPORTUNITIES
      1. ACINETOBACTER INFECTIONS TREATMENT GROWTH
    4. APPLICATION OF ACINETOBACTER INFECTIONS TREATMENT IMPACT OF COVID 19
  5. GLOBAL ACINETOBACTER INFECTIONS TREATMENT, BY TYPES
    1. INTRODUCTION
    2. SULBACTAM
    3. CARBAPENEMS
    4. AMINOGLYCOSIDES
    5. POLYMYXINS
    6. TETRACYCLINES
    7. OTHERS
  6. GLOBAL ACINETOBACTER INFECTIONS TREATMENT, BY APPLICATION
    1. INTRODUCTION
    2. ETX2514
    3. NACUBACTAM RG6080
    4. ARENICIN
    5. VXD-001
    6. SMALL MOLECULE ANTIBIOTIC
    7. AR-401 MAB
    8. LCB01-0371 (PO)
    9. GN-4474
    10. ANTIBACTERIAL ANTIBODY
  7. GLOBAL ACINETOBACTER INFECTIONS TREATMENT, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. ZOETIS INC
      2. MERCK AND COMPANY INC.
      3. BOEHRINGER INGELHEIM GMBH
      4. ELANCO ANIMAL HEALTH INC.
      5. VETOQUINOL SA
      6. VIRBAC SA
      7. PHIBRO ANIMAL HEALTH CORPORATION
      8. CEVA SANTE ANIMALE S.A
      9. COVETRUS INC.
      10. BIOGENESIS BAGO SA
      11. NEOGEN CORPORATION LTD.
      12. DECHRA PHARMACEUTICALS PLC
      13. IMMUCELL CORPORATION
      14. KRKA, TOVARNA ZDRAVIL, D. D., NOVO MESTO
      15. ECO ANIMAL HEALTH LTD

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla